GlassScriptPrepare for your visit
Paul J Kinde
Family Medicine · La Joya, TX · NPI 1396768594
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$4,102.95
in general payments reported to CMS, 2019-2025 · $672 in 2025
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Who reported paying
General payments only, top 6 by amount.
- Abbvie INC. $570.79
- Lilly USA, LLC $464.30
- Amgen INC. $364.98
- Astrazeneca Pharmaceuticals LP $284.91
- Otsuka America Pharmaceutical, INC. $258.20
- Novartis Pharmaceuticals Corporation $248.83
Drugs and devices associated with these payments
Otezla Repatha Mounjaro Rexulti Leqvio Farxiga Linzess Zepbound Paxlovid Cologuard Collection Kit Nurtec Odt Jardiance
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Paul Kinde listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/858162/paul-j-kinde